Regeneron and Sanofi's IL-4/13 immunology drug, Dupixent, was the top ad-spender for six months running. However, in November, Dupixent moved down to No. 7, with more than $23 million dropped from the advertising budget for its ads.
With this, Rybelsus and Ozempic, both Novo Nordisk’s GLP-1 diabetes medications moved into the No. 1 and No. 2 spots respectively.
Click here to see a list of the top ten advertisements in money spent.